<DOC>
	<DOCNO>NCT00149032</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation effective treatment patient resistant conventional chemotherapy . Donor lymphocytes infusion ( DLI ) serve routine treatment choice patient relapse follow allogeneic stem cell transplantation . The present proposal present introduce use immune rather naive donor lymphocytes patient resistant relapse resistant DLI . DLI prim in-vitro tumor cell host origin host alloantigens present parental alloantigens one way mixed lymphocytes culture induce much potent graft-vs-leukemia graft-vs-tumor effect , down-regulating graft-vs-host disease ( GVHD ) .</brief_summary>
	<brief_title>Treatment Patients With Donor Lymphocytes Sensitized Antigens Expressed Host</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients hematologic malignancy metastatic solid tumor relapse follow allogeneic bone marrow blood stem cell transplantation ( alloBMT ) nonmyeloablative stem cell transplantation resistant DLI GVHD take antiGVHD prophylaxis . Patients document chimerism confirm induction hostvsgraft transplantation tolerance . Patients consent participate study , minor without approved parental consent . Patients diseases complication may limit life span basic disease . Pregnant lactating woman . Noncompliant patient patient poor performance status life expectancy , e.g . 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Metastatic solid tumor</keyword>
</DOC>